Effective New Topical Treatment to Reduce Scar Formation in Burns

Period of Performance: 05/30/2013 - 12/31/2013


Phase 1 SBIR

Recipient Firm

Synedgen, Inc.
1420 N. Claremont Blvd Array
Claremont, CA 91711
Principal Investigator


Thermal injury is common in military conflicts due to primarily to the widespread use of explosive devices. Burns can produce scars that are excessive, physically debilitating and functionally damaging. There is a critical need for an effective product that can control bacterial contamination and prevent colonization, mitigate inflammation, and diffuse to or reach necrotic and damaged tissue resulting from a blast or traumatic thermal wound to reduce the formation of fibrotic scars. Synedgen has developed a biocompatible polysaccharide derivative (PAAG) that has been demonstrated in vivo and in vitro to reduce inflammation and provide enhanced healing with the reduction of scarring. This Phase 1 study will demonstrate the extent to which PAAG mitigates scar reduction in full thickness burns in a porcine model, and provide an opportunity to examine innate immune responses, inflammatory cytokines and healing pathways.